Table 3.
Univariate and multivariate analysis for NAbs titers <50% among patients with symptomatic MM on day 50.
| Variable | Univariate analysis OR, 95% CI | Multivariate OR, 95% CI |
|---|---|---|
| Age | 0.99, 0.98–1.01 | – |
| Gender | – | – |
| Males (reference) | ||
| Females | 0.6, 0.4–0.9 | – |
| BMI | 1.03, 0.98, 1.09 | – |
| Disease type (vs. controls) | Omitted due to collinearity | |
| Multiple myeloma | 3.7, 2.4–5.7 | – |
| MGUS | 0.8, 0.3–2.5 | – |
| Smoldering multiple myeloma | 2.8, 1.3–5.8 | – |
| ISS | – | |
| Stage I (reference) | ||
| Stage II | 0.76, 0.4–1.4 | – |
| Stage III | 1.5, 0.8–3 | – |
| RISS | ||
| Stage I (reference) | – | – |
| Stage II | 1.7, 0.8–3.5 | – |
| Stage III | 1.7, 0.6–5.1 | – |
| Myeloma type | ||
| IgG (reference) | ||
| IgA | 1.07, 0.5–2.3 | – |
| IgM | 0.75, 0.1–4.7 | – |
| KLC | 1, 0.4–2.5 | – |
| LLC | 1.9, 0.7–3.5 | – |
| Lymphopenia (<1000 cells/cm3) | 3.5, 1.8–6.7 | 2.1, 1–4.5 |
| Immunoparesis | ||
| IgA<70 mg/dl | 2.9, 1.8–4.4 | – |
| IgM<40 mg/dl | 1 | – |
| IgG<700 mg/dl | 1.7, 0.4-3.1 | – |
| Treatment type | ||
| Off-treatment (reference) | ||
| Anti-BCMA-based regimens | 9.4, 1.7–51.1 | 7.6, 1.4–42.4 |
| Anti-CD38-based regimens | 2.9, 1.2–7.1 | 2.4, 2.9–6.2* |
| PI/IMID-based combinations | 1.8, 0.8–4.3 | – |
| Lenalidomide maintenance | 0.9, 0.3–2.6 | – |
MM multiple m yeloma, BMI body mass index, ISS International Staging System, R-ISS Revised International Staging System, IgG immunoglobulin G, IgA immunoglobulin A, IgM immunoglobulin M, PI proteasome inhibitor, IMiD immunomodulatory drug, OR odds ratio, CI confidence interval.
*p = 0.07.
Italics denote statistical significance.